1-苯基-3-丙-2-烯基-1,2,4,5-四氢-3-苯并氮杂卓-7,8-二醇 | 104422-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 1-苯基-3-丙-2-烯基-1,2,4,5-四氢-3-苯并氮杂卓-7,8-二醇
• 英文名称: SKF 77434
• 英文别名: (+/-)-SKF 77434；3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine；N-allyl-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol；3-allyl-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzazepine-7,8-diol；SKF-77434；SKF77434；3-Allyl-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine；5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol
• CAS: 104422-04-0
• 化学式: C₁₉H₂₁NO₂
• 分子量: 295.381
• InChiKey: QBUVZVXIRYFENV-UHFFFAOYSA-N

物化性质

• 溶解度：
  乙醇：3.2 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-苯基-3-丙-2-烯基-1,2,4,5-四氢-3-苯并氮杂卓-7,8-二醇 在 磺酰氯 、 溶剂黄146 作用下， 生成 3-allyl-6,9-dichloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
  参考文献：
  名称：

  （+/-）-3-烯丙基-6-溴-7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并ze庚因，一种新的高亲和力D1多巴胺受体配体：合成与构效关系。

  摘要：

  7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并ze庚因形成一系列对D1多巴胺受体具有高亲和力的化合物。先前已证明6-氯衍生物具有增强的亲和力，选择性和激动剂活性。为了研究取代6-氯取代6-溴的效果，我们合成了一系列化合物并评估了它们对D1受体的亲和力。结果表明6-溴衍生物与6-氯衍生物具有几乎相同的亲和力，这一发现与D1拮抗剂7-卤代-8-羟基-1-苯基-2,3,4,5-相似。四氢-1H-3-苯并ze庚因系列。从目前的工作来看，3-allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4，

  DOI：

  10.1021/jm00116a004
• 作为产物：
  描述：

  (±)-1-苯基-2,3,4,5-四氢-(1H)-3-苯并ze庚因-7,8-二醇氢溴酸盐 、 3-溴丙烯 在 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 生成 1-苯基-3-丙-2-烯基-1,2,4,5-四氢-3-苯并氮杂卓-7,8-二醇
  参考文献：
  名称：

  （+/-）-3-烯丙基-6-溴-7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并ze庚因，一种新的高亲和力D1多巴胺受体配体：合成与构效关系。

  摘要：

  7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并ze庚因形成一系列对D1多巴胺受体具有高亲和力的化合物。先前已证明6-氯衍生物具有增强的亲和力，选择性和激动剂活性。为了研究取代6-氯取代6-溴的效果，我们合成了一系列化合物并评估了它们对D1受体的亲和力。结果表明6-溴衍生物与6-氯衍生物具有几乎相同的亲和力，这一发现与D1拮抗剂7-卤代-8-羟基-1-苯基-2,3,4,5-相似。四氢-1H-3-苯并ze庚因系列。从目前的工作来看，3-allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4，

  DOI：

  10.1021/jm00116a004

文献信息

• Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
  申请人：PFIZER INC.

  公开号：US20150344490A1

  公开（公告）日：2015-12-03

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

  本发明提供了部分式I的化合物及其药学上可接受的盐和N-氧化物；其制备的过程和中间体；以及其组合物和用途。本发明还提供了具有降低D1R失效的D1激动剂，具有相对于多巴胺降低β-阻滞素招募活性的D1激动剂，当结合到D1R时与Ser188显著相互作用但与Ser202显著不相互作用的D1激动剂，当结合到D1R时与Asp103相互作用较弱且与Ser198相互作用较弱的D1激动剂，以及它们的用途。
• Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0002327A1

  公开（公告）日：1979-06-13

  6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-IH-3-benzazepines of formula: in which: R is a lower alkyl of 1-6 carbons; R, is hydrogen, benzyl, phenethyl, lower alkanoyl of 1-5 carbons, lower alkyl of 1-5 carbons, lower alkyenyl of 3-5 carbons, furyl methyl, thienylmethyl or phenacyl; R2 and R3 are each hydrogen, lower alkyl of 1-5 carbons, lower alkanoyl of 2-5 carbons, benzyl or, when taken together, methylene; and R4 is hydrogen or one or two substituents from the group comprising trifluoromethyl, halo, methyl, methoxy, acetoxy, hydroxy or methylthio; or pharmaceutically acceptable, acid addition salts thereof show dopaminergic activity. Intermediates and chemical methods for preparing them are described. An important species is 6-methyl-7,8-dihydroxy-l(p-hydroxyphenyl) -2,3,4,5- tetrahydro -1N-3- benzazepine, as the base or one of its salts, which has antihypertensive activity.

  式中的 6-低级烷基-7,8-二羟基-1-苯基-2,3,4,5-四氢-IH-3-苯并氮杂卓： 其中 R是1-6个碳原子的低级烷基； R，是氢、苄基、苯乙基、1-5 个碳原子的低级烷酰基、1-5 个碳原子的低级烷基、3-5 个碳原子的低级烯基、呋喃甲基、噻吩甲基或苯乙基； R2 和 R3 分别是氢、1-5 个碳原子的低级烷基、2-5 个碳原子的低级烷酰基、苄基或合起来是亚甲基；以及 R4 是氢或来自三氟甲基、卤代、甲基、甲氧基、乙酰氧基、羟基或甲硫基等组的一个或两个取代基；或其药学上可接受的酸加成盐 显示多巴胺能活性。 本文介绍了中间体和制备它们的化学方法。其中一种重要的中间体是 6-甲基-7,8-二羟基-l（对羟基苯基）-2,3,4,5-四氢-1N-3-苯并氮杂卓，它的碱或盐具有抗高血压活性。
• Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-position modifications
  作者：Stephen T. Ross、Robert G. Franz、Gregory Gallagher、Martin Brenner、James W. Wilson、Robert M. DeMarinis、J. Paul Hieble、Henry M. Sarau

  DOI：10.1021/jm00384a006

  日期：1987.1

  The N-allyl derivative (SK&F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK&F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity. In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group. A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6-position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype. DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay. Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound; replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency. Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency. Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately potent in both assays.
• Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
  申请人：EMORY UNIVERSITY

  公开号：US20160317474A1

  公开（公告）日：2016-11-03

  This disclosure relates to managing diabetes induced visual dysfunctions or vision loss by altering levels of dopamine. In certain embodiments, the disclosure relates to methods of treating or preventing visual dysfunction or loss of vision comprising administering an effective amount of dopamine, derivative, ester, prodrug, or salt thereof to a subject wherein the subject is at risk of, exhibiting symptoms of or diagnosed with diabetes or diabetic retinopathy.
• THERAPEUTIC AGENT FOR NEUROPATHY IN ORGANIC ACIDEMIA OF WHICH MECHANISM RELIES ON INCREASE IN CAMP
  申请人：NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY

  公开号：US20200046676A1

  公开（公告）日：2020-02-13

  [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.